FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366782730> ?p ?o ?g. }

• W4366782730 abstract "Abstract Background Breast cancer is considered the most prevalent type of cancer in women and accounts for a high rate of death. A body of research has demonstrated that lncRNAs have a regulatory function in human diseases, especially cancers. ZEB2‐AS1 is known as an oncogenic lncRNA in various types of cancers, and its deregulation may contribute to cancer development and progression. Therefore, we aimed to reveal the association of ZEB2‐AS1 expression with epithelial–mesenchymal transition (EMT) markers, as a hallmark of cancer progression, in a clinical setting. Methods A recent study suggested that ZEB2‐AS1 is significantly involved in EMT. Here we intended to explore the roles of lncRNA ZEB2‐AS1 in breast cancer (BC) using bioinformatics tools and laboratory settings. We first evaluated the expression of ZEB2‐AS1 mRNA in tumor and healthy control tissues by lnCAR database. Furthermore, ZEB2‐AS1 expression level, ZEB2, E‐cadherin, and vimentin was measured via qRT‐PCR in 30 paired ductal and lobular carcinoma tissues from breast cancer patients and the normal adjacent ones. The correlation between the lncRNA ZEB2‐AS1 expression and clinicopathological characteristics of the breast cancer patients was evaluated. Results ZEB2‐AS1 showed an upregulation in breast cancer tissues ( p = .04) compared to normal adjacent samples. In addition, its level was higher in breast cancer patients with advanced Stages (III & IV) ( n = 18) compared to early Stages (I & II) ( n = 12) ( p = .04). Moreover, ZEB2 ( p = .01) and vimentin ( p = .02) expression were upregulated in the BC sample, but the expression level of E‐cadherin ( p = .02) was downregulated when compared with the adjacent normal tissues. By comparison of the expression of EMT‐markers between different stages of breast cancer, overexpression of ZEB2 ( p = .04) and vimentin ( p = .04) and down expression of E‐cadherin ( p = .03) was observed in advance stages. Conclusions Collectively, our findings suggest that ZEB2‐AS1 expression is significantly upregulated in tumor tissues, especially in advanced stages and ZEB2‐AS1 is associated with the aggressiveness of tumors by functioning as putative oncogenic lncRNA. In addition, a combination of ZEB2‐AS1 and these EMT markers in breast cancer potentiates these genes as biomarkers for tumor progression." @default.
• W4366782730 created "2023-04-25" @default.
• W4366782730 creator A5030958198 @default.
• W4366782730 creator A5061490171 @default.
• W4366782730 creator A5075780480 @default.
• W4366782730 creator A5081591137 @default.
• W4366782730 date "2023-04-23" @default.
• W4366782730 modified "2023-09-28" @default.
• W4366782730 title "Clinical significance of long non‐coding <scp>RNA ZEB2‐AS1</scp> and <scp>EMT</scp>‐related markers in ductal and lobular breast cancer" @default.
• W4366782730 cites W1985450307 @default.
• W4366782730 cites W2117977572 @default.
• W4366782730 cites W2124053507 @default.
• W4366782730 cites W2145063352 @default.
• W4366782730 cites W2162547088 @default.
• W4366782730 cites W2531423346 @default.
• W4366782730 cites W2613447387 @default.
• W4366782730 cites W2768438101 @default.
• W4366782730 cites W2799876968 @default.
• W4366782730 cites W2799898775 @default.
• W4366782730 cites W2800216524 @default.
• W4366782730 cites W2803866375 @default.
• W4366782730 cites W2909185428 @default.
• W4366782730 cites W2915264796 @default.
• W4366782730 cites W2918439356 @default.
• W4366782730 cites W2921808877 @default.
• W4366782730 cites W2929375473 @default.
• W4366782730 cites W2939774129 @default.
• W4366782730 cites W2940644952 @default.
• W4366782730 cites W2944895385 @default.
• W4366782730 cites W2946657092 @default.
• W4366782730 cites W2972304950 @default.
• W4366782730 cites W3007208321 @default.
• W4366782730 cites W3019046237 @default.
• W4366782730 cites W3021568391 @default.
• W4366782730 cites W3042954029 @default.
• W4366782730 cites W3043502121 @default.
• W4366782730 cites W3119107460 @default.
• W4366782730 cites W3129652500 @default.
• W4366782730 cites W3138217204 @default.
• W4366782730 cites W4366782730 @default.
• W4366782730 cites W3048198655 @default.
• W4366782730 doi "https://doi.org/10.1002/cnr2.1826" @default.
• W4366782730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37088469" @default.
• W4366782730 hasPublicationYear "2023" @default.
• W4366782730 type Work @default.
• W4366782730 citedByCount "1" @default.
• W4366782730 countsByYear W43667827302023 @default.
• W4366782730 crossrefType "journal-article" @default.
• W4366782730 hasAuthorship W4366782730A5030958198 @default.
• W4366782730 hasAuthorship W4366782730A5061490171 @default.
• W4366782730 hasAuthorship W4366782730A5075780480 @default.
• W4366782730 hasAuthorship W4366782730A5081591137 @default.
• W4366782730 hasBestOaLocation W43667827301 @default.
• W4366782730 hasConcept C104317684 @default.
• W4366782730 hasConcept C121608353 @default.
• W4366782730 hasConcept C126322002 @default.
• W4366782730 hasConcept C127561419 @default.
• W4366782730 hasConcept C143998085 @default.
• W4366782730 hasConcept C147447768 @default.
• W4366782730 hasConcept C204232928 @default.
• W4366782730 hasConcept C2779013556 @default.
• W4366782730 hasConcept C2780862961 @default.
• W4366782730 hasConcept C502942594 @default.
• W4366782730 hasConcept C530470458 @default.
• W4366782730 hasConcept C54355233 @default.
• W4366782730 hasConcept C62203573 @default.
• W4366782730 hasConcept C71924100 @default.
• W4366782730 hasConcept C76419328 @default.
• W4366782730 hasConcept C86803240 @default.
• W4366782730 hasConceptScore W4366782730C104317684 @default.
• W4366782730 hasConceptScore W4366782730C121608353 @default.
• W4366782730 hasConceptScore W4366782730C126322002 @default.
• W4366782730 hasConceptScore W4366782730C127561419 @default.
• W4366782730 hasConceptScore W4366782730C143998085 @default.
• W4366782730 hasConceptScore W4366782730C147447768 @default.
• W4366782730 hasConceptScore W4366782730C204232928 @default.
• W4366782730 hasConceptScore W4366782730C2779013556 @default.
• W4366782730 hasConceptScore W4366782730C2780862961 @default.
• W4366782730 hasConceptScore W4366782730C502942594 @default.
• W4366782730 hasConceptScore W4366782730C530470458 @default.
• W4366782730 hasConceptScore W4366782730C54355233 @default.
• W4366782730 hasConceptScore W4366782730C62203573 @default.
• W4366782730 hasConceptScore W4366782730C71924100 @default.
• W4366782730 hasConceptScore W4366782730C76419328 @default.
• W4366782730 hasConceptScore W4366782730C86803240 @default.
• W4366782730 hasFunder F4320327362 @default.
• W4366782730 hasIssue "5" @default.
• W4366782730 hasLocation W43667827301 @default.
• W4366782730 hasLocation W43667827302 @default.
• W4366782730 hasLocation W43667827303 @default.
• W4366782730 hasOpenAccess W4366782730 @default.
• W4366782730 hasPrimaryLocation W43667827301 @default.
• W4366782730 hasRelatedWork W1559117395 @default.
• W4366782730 hasRelatedWork W1652355491 @default.
• W4366782730 hasRelatedWork W2312941871 @default.
• W4366782730 hasRelatedWork W2593898132 @default.
• W4366782730 hasRelatedWork W2614825660 @default.
• W4366782730 hasRelatedWork W2774531037 @default.
• W4366782730 hasRelatedWork W2905097265 @default.
• W4366782730 hasRelatedWork W2919229222 @default.

• next